Nucleotica at ESHG 2025: Advancing Dialogue in Human Genetics
Milan, June 2025 — Nucleotica was honored to participate in the European Human Genetics Conference (ESHG 2025), held this June in Milan. As one of the world’s premier forums for the latest advancements in genetics, diagnostics, and biotechnological innovation, the event brought together leading researchers, clinicians, and industry stakeholders from across the globe.
Representing Nucleotica at the event was Sergey Yetka, Director of International Sales, who engaged with experts and potential partners over the course of three days of productive dialogue, presentations, and collaboration.
“The level of engagement and interest in our DNA and RNA diagnostics platform was truly encouraging,” said Sergey. “We had the opportunity to speak with dozens of researchers, clinicians, and technology professionals who are deeply invested in improving the future of precision diagnostics — and who recognized the potential of what we’re building at Nucleotica.”
During the conference, Sergey presented Nucleotica’s proprietary molecular diagnostics platform, with a focus on technologies enabling rapid and highly sensitive detection of somatic mutations, including KRAS SNPs — a key marker in oncology diagnostics and treatment planning. The discussions underscored a strong market need for adaptable, clinically integrated tools that support personalized approaches to healthcare.
“I returned from ESHG with new ideas, new connections, and a renewed sense of purpose,” Sergey noted. “Several conversations hold real promise for scientific collaboration and strategic partnerships.”
We extend our sincere thanks to the organizers of ESHG 2025 and to all who visited, exchanged ideas, or explored future synergies with Nucleotica. Among the professionals we were pleased to meet and learn from: Anna Lejon, Andreas Kegel, Emma Hahlin, Małgorzata Marcinkowska-Swojak, Maria Weronika Gutowska-Ding, Marina Konyukh, Valentina Trevisan, Pawel Szyld, Shalini Roy Choudhury, Sophia Rasmussen, and many others.
About Nucleotica
Nucleotica is a biotechnology company developing high-performance molecular diagnostics for oncology, infectious diseases, and personalized medicine. Through a combination of next-generation sensor platforms and clinical integration, Nucleotica aims to deliver accurate, scalable, and accessible tools for the future of healthcare.
